Skip to main content
OpenTrials
Completed

NCT Number: NCT01114594

Pilot Study of RNA as a Biomarker for Autosomal Dominant Polycystic Kidney Disease

The aim of this pilot project is to assess the potential of urine micro-RNAs (miRNA) as biomarkers for characterizing patients with autosomal dominant polycystic kidney disease (ADPKD) compared with patients with other causes of chronic kidney disease.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Proteins and small molecules in urine (biomarkers) have been used to probe for kidney and systemic diseases for hundreds of years. Urine reportedly contains a type of molecule called microRNA (miRNAs) that regulate a large number of biological processes. Impaired function of miRNAs is now recognized in an increasing number of disease processes. In the search for new biomarkers, the regulatory function of miRNAs and the relative simplicity and precision of characterizing miRNAs, are potential advantages when compared to traditional biomarkers.

The aim of this pilot project is to assess the potential of urine miRNAs as biomarkers for characterizing patients with autosomal dominant polycystic kidney disease (ADPKD), the most prevalent inherited cause of kidney failure. Individuals with other causes of chronic kidney disease (e.g., diabetes, glomerulonephritis), who are matched for key characteristics (e.g. age, sex, level of kidney function) will serve as the control population. A technique for isolation of miRNAs from urine samples will be tailored for the specific needs of this project. Biochemical and computational analysis of small RNAs from these samples will provide urine miRNA profiles and key variability statistics that will be use to design follow-up projects involving patients with kidney disease.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female subject, 18 years of age or older, with diagnosis of ADPKD or non-PKD-CKD
  • If female, not pregnant.
  • Willing and able to understand and sign informed consent

Exclusion criteria

  • Presenting with any signs or symptoms of an infectious disease
  • Bacterial infection determined by urine culture
  • Use of systemic steroids within a week prior to screening
  • History, physical, or laboratory findings suggestive of any other medical or psychological condition that would, in the opinion of the Principal Investigator, make the candidate ineligible for the study.

Treatment and study plan

Primary outcomes

  1. Identification of micro-RNA Biomarkers Associated with Autosomal Dominant Chronic Kidney Disease

    Time frame: 5 years

Sponsors and collaborators

Lead sponsor

The Rogosin Institute

Other

Collaborators

  • Rockefeller University
  • Weill Medical College of Cornell University

Registry information

Important dates

Study start
2010
Primary completion
2012
Study completion
2012
First posted
May 3, 2010
Registry last updated
Nov 6, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.